Table 3.
No. | Author | Year | Age/Sex | Outcome | Treatment | ClinicalManifestation | Host | CD4+ (cells/m3) | Country | Organ involvement |
---|---|---|---|---|---|---|---|---|---|---|
1 | Ledford et al. (1985) | 1985 | 20/M | Recovery | TPM/SMX | Generalized muscle weakness, fever, weight loss lymphadenopathy |
AIDS | N/A | U.S.A. | Sinuses, muscle, testicular failure, hypoandrogenism |
2 | Chupp et al. (1993) | 1993 | 33/M | Death | Pyrimethamine clindamycin |
Fever, productive cough, myalgias, weakness | AIDS | N/A | Haiti | Skeletal muscle |
3 | Grau et al. (1996) | 1996 | N/A | Article in Spanish | Article in Spanish | Myositis, fever | AIDS | N/A | Article in Spanish | Muscle |
4 | Field et al. (1996) | 1996 | 34/M | Recovered but died of progressive HIV |
Albendazole sulfadiazine pyrimethamine |
Myalgias, diplopia, lethargy, weight loss, odynophagia, cough, fever |
AIDS | N/A | Australia | Skeletal muscle, conjunctivae, nasal sinuses |
5 | Rauz et al. (2004) | 2004 | 22/M | Recurrence | Topical Fumagillin PHMB 0.02% albendazole |
Photophobia, blurred vision |
Immuno-competent | N/A | Ghana | Eye stroma |
6 | Curry et al. (2005) | 2005 | 47/M | Death (Suicide) | N/A | Left upper lobe pneumonia |
AIDS | 30 | Australia | Pectoral muscles, myocardium |
7 | Siripaitoon et al. (2021) | 2021 | 29/F | Death | Albendazole TPM/SMX clindamycin |
Incapacitating myalgias, fever, lethargy | AIDS | 15 | Thailand | Muscle, bone marrow |
8. | Buppajarntham et al. (2021) | 2021 | 45/M | Recovery | Albendazole pyrimethamine clindamycin |
Myalgia | AIDS | 12 | Thailand | Skeletal muscle |
N/A, non-applicable.